Molecular Immunology

Mestag Therapeutics announces the appointment of expert advisors Dr. Cassandra Choe-Juliak, Dr. Greg Elson and Samantha Vieira MBA

Retrieved on: 
Thursday, October 12, 2023

"Mestag is honored to appoint Dr. Choe-Juliak, Dr. Elson and Ms Vieira to our advisory team.

Key Points: 
  • "Mestag is honored to appoint Dr. Choe-Juliak, Dr. Elson and Ms Vieira to our advisory team.
  • Cassandra Choe-Juliak, MD, MS, has spent more than 17 years in oncology medical affairs and clinical drug development.
  • Greg Elson, PhD, is co-founder and managing partner at Prevail Biopharma Solutions, and Chief Technology Officer at Alentis Therapeutics.
  • Samantha holds an EMBA from Henley Business School and BSc (Honours) in Physiology from University of the Witwatersrand, South Africa.

POINT Biopharma Announces Appointment of Dr. Bridget Martell to its Board of Directors

Retrieved on: 
Monday, June 12, 2023

INDIANAPOLIS, June 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the filling of its vacant board seat with the appointment of Bridget Martell, M.A., M.D.

Key Points: 
  • INDIANAPOLIS, June 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the filling of its vacant board seat with the appointment of Bridget Martell, M.A., M.D.
  • to its Board of Directors.
  • "On behalf of POINT and the Board of Directors, I am pleased to welcome Dr. Martell, an experienced biotech board executive who brings extensive drug development, operational, and commercial expertise in both oncology and precision medicine," said Allan Silber, Executive Chairman of POINT Biopharma.
  • She started her pharmaceutical career at Pfizer, where she had roles of increasing responsibility in both the oncology and biosimilars business units.

SHORELINE BIOSCIENCES STRENGTHENS R&D LEADERSHIP TEAM WITH SEVERAL SENIOR APPOINTMENTS

Retrieved on: 
Tuesday, February 15, 2022

Prior to that, she was Vice President, Clinical Operations for MEI Pharma, Regulus Therapeutics, and the California Institute for Biomedical Research (Calibr).

Key Points: 
  • Prior to that, she was Vice President, Clinical Operations for MEI Pharma, Regulus Therapeutics, and the California Institute for Biomedical Research (Calibr).
  • Pinky Doshi brings to Shoreline more thantwo decades of global regulatory experience within the pharmaceutical industry.
  • Before that, he served in roles of increasing responsibility at AstraZeneca in the R&D team in Lund, Sweden.
  • Shoreline Biosciences is headquartered in San Diego, CA.

Portage Biotech Announces New Appointments to its Management Team and Board of Directors

Retrieved on: 
Tuesday, February 15, 2022

WESTPORT, Conn., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced new appointments to its management team and Board of Directors. Brian Wiley, who has served in leadership roles at multiple pharmaceutical companies including Celgene and Millennium Pharmaceuticals, will join Portage’s executive team as Chief Business Officer and Joseph Ciavarella, who joined the company in 2020 as a financial consultant, now joins as Chief Accounting Officer.

Key Points: 
  • In addition, Jim Mellon, Linda M. Kozick and Mark Simon will join the companys Board of Directors.
  • The new appointments come at the cusp of an exciting new year for Portage.
  • In addition to Portage, she currently serves on the Board of Directors for RAPT Therapeutics, Inc. and Artiva Biotherapeutics.
  • For more information, please visit www.portagebiotech.com , follow us on Twitter at @PortageBiotech, or find us on LinkedIn at Portage Biotech Inc.

Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President

Retrieved on: 
Tuesday, January 4, 2022

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that Akshay Vaishnaw, M.D., Ph.D. has been appointed President.

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that Akshay Vaishnaw, M.D., Ph.D. has been appointed President.
  • Dr. Vaishnaw joined Alnylam in 2006 as Vice President, Clinical Research with roles of increasing responsibility, ultimately serving as President of Research and Development (R&D).
  • We are fortunate to have such a talented and capable scientific leader helping us achieve our Alnylam P5x25 goals.
  • Dr. Vaishnaw joined Alnylam in 2006 as Vice President, Clinical Research and has then subsequently served in various R&D roles with increasing responsibility.

Aligos Therapeutics Appoints Bridget Martell, MA, M.D., to its Board of Directors

Retrieved on: 
Thursday, November 18, 2021

We are pleased to welcome Dr. Martell to our board of directors.

Key Points: 
  • We are pleased to welcome Dr. Martell to our board of directors.
  • I look forward to supporting the Aligos team in strategically navigating their clinical development efforts.
  • Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases.
  • Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

IASO Bio Appoints Industry Veteran Dr. Alan Fu Chief Financial Officer

Retrieved on: 
Tuesday, October 19, 2021

IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases, has appointed Dr. Alan Fu as Chief Financial Officer (CFO), reporting to Maxwell Wang, CEO, IASO Bio.

Key Points: 
  • IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases, has appointed Dr. Alan Fu as Chief Financial Officer (CFO), reporting to Maxwell Wang, CEO, IASO Bio.
  • View the full release here: https://www.businesswire.com/news/home/20211019005333/en/
    Dr. Alan Fu, Chief Financial Officer (CFO), IASO Bio (Photo: Business Wire)
    As a member of the executive leadership team, Dr. Fu will oversee IASO Bios capital markets activities and financial management, and will advance the companys sustainable development in capital markets and financial operations.
  • Alan is a proven leader who brings a deep understanding of the healthcare industry and capital markets to the CFO role, said Dr. Wang.
  • IASO Bio is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases.

Artizan Biosciences Announces Appointment of Dr. Bridget Martell as President and Chief Executive Officer

Retrieved on: 
Tuesday, October 19, 2021

NEW HAVEN, Conn., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Artizan Biosciences, Inc. (Artizan), a biotechnology company at the frontier of microbiome precision medicine, today announced the appointment of Bridget Martell, M.A., M.D., as President and Chief Executive Officer.

Key Points: 
  • NEW HAVEN, Conn., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Artizan Biosciences, Inc. (Artizan), a biotechnology company at the frontier of microbiome precision medicine, today announced the appointment of Bridget Martell, M.A., M.D., as President and Chief Executive Officer.
  • Dr. Martell is a currently a member of the Board of Directors at Achieve Life Sciences and serves as a Venture Partner at AlleyCorps Healthcare Fund.
  • Using a novel small molecule approach, Artizan modulates intestinal imbalance by inhibiting specific, disease-associated microbial virulence factors in the intestinal tract.
  • Founded with IgA-SEQ technology and preeminent immunobiology expertise from Yale University, Artizan is based in New Haven, CT. For more information, please visit www.artizanbiosciences.com .